Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.

Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, Lahoutte T, De Wever O, Vanderkerken K, Menu E.

Blood. 2014 Jul 24;124(4):555-66. doi: 10.1182/blood-2014-03-562439. Epub 2014 Jun 13.

2.

Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.

Catley L, Tai YT, Shringarpure R, Burger R, Son MT, Podar K, Tassone P, Chauhan D, Hideshima T, Denis L, Richardson P, Munshi NC, Anderson KC.

Cancer Res. 2004 Dec 1;64(23):8746-53.

3.

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells.

Chauhan D, Li G, Podar K, Hideshima T, Mitsiades C, Schlossman R, Munshi N, Richardson P, Cotter FE, Anderson KC.

Blood. 2004 Oct 15;104(8):2458-66. Epub 2004 Jun 24.

5.

Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.

Que W, Chen J, Chuang M, Jiang D.

APMIS. 2012 Mar;120(3):195-203. doi: 10.1111/j.1600-0463.2011.02836.x. Epub 2011 Nov 11.

PMID:
22339676
6.

Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.

Kobayashi T, Kuroda J, Ashihara E, Oomizu S, Terui Y, Taniyama A, Adachi S, Takagi T, Yamamoto M, Sasaki N, Horiike S, Hatake K, Yamauchi A, Hirashima M, Taniwaki M.

Leukemia. 2010 Apr;24(4):843-50. doi: 10.1038/leu.2010.25. Epub 2010 Mar 4.

PMID:
20200560
7.

Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells.

Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, Raschko M, Leith CP, Kahl BS, Kim K, Miyamoto S.

Mol Cancer Res. 2008 Aug;6(8):1356-64. doi: 10.1158/1541-7786.MCR-08-0108.

8.

BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.

Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N, Anderson KC.

Br J Haematol. 2007 Feb;136(3):414-23. Epub 2006 Dec 14.

PMID:
17173546
9.

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, Anderson KC.

Cancer Res. 2001 Apr 1;61(7):3071-6.

10.

Toll-like receptor (TLR)-1/2 triggering of multiple myeloma cells modulates their adhesion to bone marrow stromal cells and enhances bortezomib-induced apoptosis.

Abdi J, Mutis T, Garssen J, Redegeld FA.

PLoS One. 2014 May 2;9(5):e96608. doi: 10.1371/journal.pone.0096608. eCollection 2014.

11.

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.

Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC.

Cancer Res. 2006 Jul 1;66(13):6675-82.

12.

A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.

Chauhan D, Li G, Podar K, Hideshima T, Neri P, He D, Mitsiades N, Richardson P, Chang Y, Schindler J, Carver B, Anderson KC.

Cancer Res. 2005 Sep 15;65(18):8350-8.

13.

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC.

Blood. 2007 Sep 1;110(5):1656-63. Epub 2007 May 17.

14.

Tipifarnib and bortezomib are synergistic and overcome cell adhesion-mediated drug resistance in multiple myeloma and acute myeloid leukemia.

Yanamandra N, Colaco NM, Parquet NA, Buzzeo RW, Boulware D, Wright G, Perez LE, Dalton WS, Beaupre DM.

Clin Cancer Res. 2006 Jan 15;12(2):591-9.

15.

INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.

Li J, Favata M, Kelley JA, Caulder E, Thomas B, Wen X, Sparks RB, Arvanitis A, Rogers JD, Combs AP, Vaddi K, Solomon KA, Scherle PA, Newton R, Fridman JS.

Neoplasia. 2010 Jan;12(1):28-38.

16.

Targeting receptor kinases by a novel indolinone derivative in multiple myeloma: abrogation of stroma-derived interleukin-6 secretion and induction of apoptosis in cytogenetically defined subgroups.

Bisping G, Kropff M, Wenning D, Dreyer B, Bessonov S, Hilberg F, Roth GJ, Munzert G, Stefanic M, Stelljes M, Scheffold C, Müller-Tidow C, Liebisch P, Lang N, Tchinda J, Serve HL, Mesters RM, Berdel WE, Kienast J.

Blood. 2006 Mar 1;107(5):2079-89. Epub 2005 Nov 8.

17.

Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells.

Markovina S, Callander NS, O'Connor SL, Xu G, Shi Y, Leith CP, Kim K, Trivedi P, Kim J, Hematti P, Miyamoto S.

Mol Cancer. 2010 Jul 6;9:176. doi: 10.1186/1476-4598-9-176.

18.

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.

Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, Alt C, Burwick N, Roccaro AM, Ngo HT, Farag M, Melhem MR, Sacco A, Munshi NC, Hideshima T, Rollins BJ, Anderson KC, Kung AL, Lin CP, Ghobrial IM.

Blood. 2009 Apr 30;113(18):4341-51. doi: 10.1182/blood-2008-10-186668. Epub 2009 Jan 12.

19.

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, Schlossman R, Podar K, Munshi NC, Mitsiades N, Anderson KC.

Blood. 2003 Feb 15;101(4):1530-4. Epub 2002 Sep 26.

20.

Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells.

Park J, Ayyappan V, Bae EK, Lee C, Kim BS, Kim BK, Lee YY, Ahn KS, Yoon SS.

Mol Oncol. 2008 Dec;2(4):317-26. doi: 10.1016/j.molonc.2008.09.006. Epub 2008 Oct 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk